ropeginterferon vs standard therapy for polycythemia vera
Published 4 years ago • 580 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
2:06
clinical updates on the use of ropeginterferon for polycythemia vera
-
1:29
ropeginterferon alfa-2b for polycythemia vera: impacts and considerations
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
3:19
targeting jak2 v617f vaf in polycythemia vera & the efficacy of ropeginterferon alfa-2b
-
10:56
identifying and communicating your polycythemia vera (pv) symptoms
-
12:06
can patients with polycythemia vera (pv) live a normal lifespan?
-
6:01
common signs and symptoms of polycythemia vera
-
10:20
new guidelines for the treatment and management of polycythemia vera
-
2:05
ropeg in polycythemia vera: long-term proud-pv and conti-pv results
-
6:31
the current treatment landscape for polycythemia vera
-
2:54
an update on the use of idasanutlin in polycythemia vera
-
3:10
promising trials in polycythemia vera
-
1:59
surpass et: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia
-
2:46
an update on emerging therapies for the treatment of polycythemia vera
-
3:00
ropeginterferon alpha-2b as an effective treatment against pv
-
3:15
updates on ropeginterferon in pv
-
1:30
the patient perspective of polycythemia vera and second-line treatment options
-
2:40
safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
-
3:02
pilot study of ropeginterferon in early myelofibrosis
-
1:39
upcoming agents in et and pv
-
1:41
updates on ropeginterferon in mpns